Overview
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.
Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Founders & team
Previously EUGIT Tx, EUGIT Therapeutics, Eugit, Eugit Therapeutics Inc
Nizar Batada
Founder/CEONizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.
Founded 2022 · Source ↗
Sources & observations
Y Combinator
Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedSan Francisco, CA, USA; South San Francisco, CA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented
Source-based assessment · automated evidence rules
The captured homepage does not clearly identify the listed business.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
Stage definitionsindependent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
